

CLAIMS AMENDMENTS

Please amend claims 1, and 66-150, as shown below. All other claims are unchanged.

1 1. (currently amended) A preparation for topically delivering
2 and localizing at least one therapeutic agent, comprising:
3 a vasoconstrictor for retarding vascular dispersion of a
4 therapeutic agent, selected from the vasoconstrictor group
5 consisting of at least one of: *phenylephrine, ephedrine sulfate,*
6 *epinephrine, naphazoline, and oxymetazoline*; and
7 a penetration enhancer for facilitating penetration of said
8 vasoconstrictor and said therapeutic agent through a patient's
9 skin, selected from the penetration enhancer group consisting of
10 at least one of: *lecithin and dimethylsulfoxide*; wherein:
11 said therapeutic agent is selected from the therapeutic-
12 agent group consisting of at least one of therapeutic agent in at
13 least one of the following therapeutic agent groups:
14 (a) a local anesthetic selected from the group consisting
15 of: *bupivacaine, mepivacaine, levobupivacaine, ropivacaine,*
16 *chloroprocaine, procaine, lidocaine, etidocaine, benzocaine,*
17 *tetracaine, and prilocaine*;
18 (b) a quick-onset, short-acting non-steroidal anti-
19 inflammatory agent selected from the group consisting of:
20 *ketoprofen, diclofenac, diflunisal, etodolac, fenoprofen,*
21 *flurbiprofen, ibuprofen, indomethacin, and tolmetin*;

22 (c) a long-acting non-steroidal anti-inflammatory agent
23 selected from the group consisting of: *piroxicam, celecoxib,*
24 *meloxicam, nabumetone, naproxen, oxaprozin, rofecoxib, sulindac,*
25 *and valdecoxib*; and

26 (d) an antiviral agent selected from the group consisting
27 of: *2-deoxy-d-glucose, podofilox, acyclovir, penciclovir, and*
28 *docusanol.*

1 2. (withdrawn, original) The preparation of claim 1, said
2 vasoconstrictor comprising *phenylephrine*.

1 3. (withdrawn, original) The preparation of claim 2, wherein:
2 a clinical concentration of said *phenylephrine* is at least
3 approximately 0.125%; and

4 said clinical concentration of said *phenylephrine* is at
5 most approximately 1.0%.

1 4. (withdrawn, original) The preparation of claim 3, wherein
2 said clinical concentration of said *phenylephrine* is
3 approximately 0.5%.

1 5. (withdrawn, original) The preparation of claim 1, said
2 vasoconstrictor comprising a vasoconstrictor selected from the
3 vasoconstrictor group consisting of: *ephedrine sulfate,*
4 *epinephrine, naphazoline, and oxymetazoline.*

1 6. (withdrawn, original) The preparation of claim 1, said
2 penetration enhancer comprising *dimethylsulfoxide.*

1 7. (withdrawn, original) The preparation of claim 6, wherein

2 a clinical concentration of said *dimethylsulfoxide* is at most
3 approximately 10%.

1 8. (withdrawn, original) The preparation of claim 7, wherein
2 said clinical concentration of said *dimethylsulfoxide* is
3 approximately 10%.

1 9. (withdrawn, original) The preparation of claim 1, said
2 penetration enhancer comprising *lecithin*.

1 10. (withdrawn, original) The preparation of claim 9, said
2 penetration enhancer further comprising *ethoxy diglycol*.

1 11. (withdrawn, original) The preparation of claim 9, wherein:
2 a clinical concentration of said *lecithin* is at least
3 approximately 2%; and

4 said clinical concentration of said *lecithin* is at most
5 approximately 50%.

1 12. (withdrawn, original) The preparation of claim 11,
2 wherein:

3 said clinical concentration of said *lecithin* is
4 approximately 10% to 12%.

1 13. (withdrawn, original) The preparation of claim 1:
2 said vasoconstrictor comprising *phenylephrine*; and
3 said penetration enhancer comprising *dimethylsulfoxide*.

1 14. (withdrawn, original) The preparation of claim 13,
2 wherein:

3 a clinical concentration of said *phenylephrine* is at least

4 approximately 0.125%;

5 said clinical concentration of said *phenylephrine* is at
6 most approximately 1.0%; and

7 a clinical concentration of said *dimethylsulfoxide* is at
8 most approximately 10%.

1 15. (withdrawn, original) The preparation of claim 14,
2 wherein:

3 said clinical concentration of said *phenylephrine* is
4 approximately 0.5%; and

5 said clinical concentration of said *dimethylsulfoxide* is
6 approximately 10%.

1 16. (withdrawn, original) The preparation of claim 13,
2 wherein:

3 a ratio of a clinical concentration of said
4 *dimethylsulfoxide* to a clinical concentration of said
5 *phenylephrine* is at most approximately 40 to 1.

1 17. (withdrawn, original) The preparation of claim 1:
2 said vasoconstrictor comprising *phenylephrine*; and
3 said penetration enhancer comprising *lecithin*.

1 18. (withdrawn, original) The preparation of claim 17, said
2 penetration enhancer further comprising *ethoxy diglycol*.

1 19. (withdrawn, original) The preparation of claim 17,
2 wherein:

3 a clinical concentration of said *phenylephrine* is at least

4 approximately 0.125%;

5 said clinical concentration of said *phenylephrine* is at
6 most approximately 1.0%; and

7 a clinical concentration of said *lecithin* is at most
8 approximately 50%.

1 20. (withdrawn, original) The preparation of claim 19,
2 wherein:

3 said clinical concentration of said *phenylephrine* is
4 approximately 0.5%; and

5 said clinical concentration of said *lecithin* is
6 approximately 10% to 12%.

1 21. (withdrawn, original) The preparation of claim 17,
2 wherein:

3 a ratio of a clinical concentration of said *lecithin* to a
4 clinical concentration of said *phenylephrine* is at most
5 approximately 200 to 1.

1 22. (withdrawn, original) The preparation of claim 1, further
2 comprising:

3 said therapeutic agent.

1 23. (withdrawn, original) The preparation of claim 22,
2 particularly for relieving pain, comprising:

3 said therapeutic agent comprising a therapeutic pain-
4 relieving agent;

5 said penetration enhancer for facilitating penetration of

6 said therapeutic pain-relieving agent and said vasoconstrictor
7 through the patient's skin; and
8 said vasoconstrictor for retarding vascular dispersion of
9 said therapeutic agent.

1 24. (withdrawn, original) The preparation of claim 23, said
2 therapeutic pain-relieving agent comprising:
3 a local anesthetic.

1 25. (withdrawn, original) The preparation of claim 24, said
2 local anesthetic comprising *bupivacaine*.

1 26. (withdrawn, original) The preparation of claim 25,
2 wherein:

3 a clinical concentration of said *bupivacaine* is at least
4 approximately 2%; and

5 said clinical concentration of said *bupivacaine* is at most
6 approximately 10%.

1 27. (withdrawn, original) The preparation of claim 26, wherein
2 said clinical concentration of said *bupivacaine* is approximately
3 5%.

1 28. (withdrawn, original) The preparation of claim 24, said
2 local anesthetic comprising a local anesthetic selected from the
3 local anesthetic group consisting of: *mepivacaine*,
4 *levobupivacaine*, *ropivacaine*, *chloroprocaine*, *procaine*,
5 *lidocaine*, *etidocaine*, *benzocaine*, *tetracaine*, and *prilocaine*.

1 29. (withdrawn, original) The preparation of claim 23, said

2 therapeutic pain-relieving agent comprising:

3 a quick-onset, short-acting non-steroidal anti-inflammatory
4 agent.

1 30. (withdrawn, original) The preparation of claim 29, said
2 quick-onset, short-acting non-steroidal anti-inflammatory agent
3 comprising *ketoprofen*.

1 31. (withdrawn, original) The preparation of claim 30,
2 wherein:

3 a clinical concentration of said *ketoprofen* is at least
4 approximately 5%; and

5 said clinical concentration of said *ketoprofen* is at most
6 approximately 20%.

1 32. (withdrawn, original) The preparation of claim 31, wherein
2 said clinical concentration of said *ketoprofen* is approximately
3 10%.

1 33. (withdrawn, original) The preparation of claim 29, said
2 quick-onset, short-acting non-steroidal anti-inflammatory agent
3 comprising a quick-onset, short-acting non-steroidal anti-
4 inflammatory agent selected from the quick-onset, short-acting
5 non-steroidal anti-inflammatory agent group consisting of:
6 *diclofenac*, *diflunisal*, *etodolac*, *fenoprofen*, *flurbiprofen*,
7 *ibuprofen*, *indomethacin*, and *tolmetin*.

1 34. (withdrawn, original) The preparation of claim 23, said
2 therapeutic pain-relieving agent comprising:

3 a long-acting non-steroidal anti-inflammatory agent.

1 35. (withdrawn, original) The preparation of claim 34, said
2 long-acting non-steroidal anti-inflammatory agent comprising
3 *piroxicam*.

1 36. (withdrawn, original) The preparation of claim 35,
2 wherein:

3 a clinical concentration of said *piroxicam* is at least
4 approximately 0.5%; and

5 said clinical concentration of said *piroxicam* is at most
6 approximately 4%.

1 37. (withdrawn, original) The preparation of claim 36, wherein
2 said clinical concentration of said *piroxicam* is approximately
3 1.0%.

1 38. (withdrawn, original) The preparation of claim 34, said
2 long-acting non-steroidal anti-inflammatory agent comprising a
3 long-acting non-steroidal anti-inflammatory agent selected from
4 the long-acting non-steroidal anti-inflammatory agent group
5 consisting of: *celecoxib*, *meloxicam*, *nabumetone*, *naproxen*,
6 *oxaprozin*, *rofecoxib*, *sulindac*, and *valdecoxib*.

1 39. (withdrawn, original) The preparation of claim 23, said
2 therapeutic pain-relieving agent comprising:

3 a local anesthetic; and

4 a quick-onset, short-acting non-steroidal anti-inflammatory
5 agent.

1 40. (withdrawn, original) The preparation of claim 39:
2 said local anesthetic comprising *bupivacaine*; and
3 said quick-onset, short-acting non-steroidal anti-
4 inflammatory agent comprising *ketoprofen*.

1 41. (withdrawn, original) The preparation of claim 23, said
2 therapeutic pain-relieving agent comprising:
3 a local anesthetic; and
4 a long-acting non-steroidal anti-inflammatory agent.

1 42. (withdrawn, original) The preparation of claim 41:
2 said local anesthetic comprising *bupivacaine*; and
3 said long-acting non-steroidal anti-inflammatory agent
4 comprising *piroxicam*.

1 43. (withdrawn, original) The preparation of claim 23, said
2 therapeutic pain-relieving agent comprising:
3 a quick-onset, short-acting non-steroidal anti-inflammatory
4 agent; and
5 a long-acting non-steroidal anti-inflammatory agent.

1 44. (withdrawn, original) The preparation of claim 43:
2 said quick-onset, short-acting non-steroidal anti-
3 inflammatory agent comprising *ketoprofen*; and
4 said long-acting non-steroidal anti-inflammatory agent
5 comprising *piroxicam*.

1 45. (withdrawn, original) The preparation of claim 23, said
2 therapeutic pain-relieving agent comprising:

3 a local anesthetic;
4 a quick-onset, short-acting non-steroidal anti-inflammatory
5 agent; and
6 a long-acting non-steroidal anti-inflammatory agent.

1 46. (withdrawn, original) The preparation of claim 45:
2 said local anesthetic comprising *bupivacaine*;
3 said quick-onset, short-acting non-steroidal anti-
4 inflammatory agent comprising *ketoprofen*; and
5 said long-acting non-steroidal anti-inflammatory agent
6 comprising *piroxicam*.

1 47. (withdrawn, original) The preparation of claim 46,
2 wherein:
3 a clinical concentration of said *bupivacaine* is at least
4 approximately 2%;
5 said clinical concentration of said *bupivacaine* is at most
6 approximately 10%;
7 a clinical concentration of said *ketoprofen* is at least
8 approximately 5%;
9 said clinical concentration of said *ketoprofen* is at most
10 approximately 20%;
11 a clinical concentration of said *piroxicam* is at least
12 approximately 0.5%; and
13 said clinical concentration of said *piroxicam* is at most
14 approximately 4%.

1 48. (withdrawn, original) The preparation of claim 47,
2 wherein:

3 said clinical concentration of said *bupivacaine* is
4 approximately 5%;

5 said clinical concentration of said *ketoprofen* is
6 approximately 10%; and

7 said clinical concentration of said *piroxicam* is
8 approximately 1.0%

1 49. (withdrawn, original) The preparation of claim 22,
2 particularly for treating a viral disease, comprising:

3 said therapeutic agent comprising an antiviral agent;
4 said penetration enhancer for facilitating penetration of
5 said antiviral agent and said vasoconstrictor through the
6 patient's skin; and

7 said vasoconstrictor for retarding vascular dispersion of
8 said antiviral agent.

1 50. (withdrawn, original) The preparation of claim 49, said
2 antiviral agent comprising 2-deoxy-d-glucose.

1 51. (withdrawn, original) The preparation of claim 50,
2 wherein:

3 a clinical concentration of said 2-deoxy-d-glucose is at
4 least approximately 0.1%; and

5 said clinical concentration of said 2-deoxy-d-glucose is at
6 most approximately 0.4%.

1 52. (withdrawn, original) The preparation of claim 51,
2 wherein:

3 said clinical concentration of said 2-deoxy-d-glucose is
4 approximately 0.2%.

1 53. (withdrawn, original) The preparation of claim 49, said
2 antiviral agent comprising an antiviral agent selected from the
3 antiviral agent group consisting of: *podofilox, acyclovir,*
4 *penciclovir, and docosanol.*

1 54. (withdrawn, original) The preparation of claim 23,
2 particularly for relieving pain from a viral disease and
3 treating the viral disease, comprising:

4 said therapeutic agent further comprising an antiviral
5 agent;

6 said penetration enhancer for further facilitating
7 penetration of said antiviral agent through the patient's skin;
8 and

9 said vasoconstrictor for further retarding vascular
10 dispersion of said antiviral agent.

1 55. (withdrawn, original) The preparation of claim 54, said
2 antiviral agent comprising 2-deoxy-d-glucose.

1 56. (withdrawn, original) The preparation of claim 55,
2 wherein:

3 a clinical concentration of said 2-deoxy-d-glucose is at
4 least approximately 0.1%; and

5 said clinical concentration of said 2-deoxy-d-glucose is at
6 most approximately 0.4%.

1 57. (withdrawn, original) The preparation of claim 56,
2 wherein:

3 said clinical concentration of said 2-deoxy-d-glucose is
4 approximately 0.2%.

1 58. (withdrawn, original) The preparation of claim 54, said
2 antiviral agent comprising an antiviral agent selected from the
3 antiviral agent group consisting of: *podofilox, acyclovir,*
4 *penciclovir, and docosanol.*

1 59. (withdrawn, original) The preparation of claim 45:
2 said vasoconstrictor comprising *phenylephrine;*
3 said penetration enhancer comprising a penetration
4 enhancing agent selected from the penetration-enhancing agent
5 group consisting of *dimethylsulfoxide and lecithin;*
6 said local anesthetic comprising *bupivacaine;*
7 said quick-onset, short-acting non-steroidal anti-
8 inflammatory agent comprising *ketoprofen;* and
9 said long-acting non-steroidal anti-inflammatory agent
10 comprising *piroxicam.*

1 60. (withdrawn, original) The preparation of claim 59,
2 wherein:

3 a clinical concentration of said *phenylephrine* is at least
4 approximately 0.125%;

5 said clinical concentration of said *phenylephrine* is at
6 most approximately 1.0%;
7 a clinical concentration of said *dimethylsulfoxide* is at
8 most approximately 10%;
9 a clinical concentration of said *lecithin* is at most
10 approximately 50%;
11 a clinical concentration of said *bupivacaine* is at least
12 approximately 2%;
13 said clinical concentration of said *bupivacaine* is at most
14 approximately 10%;
15 a clinical concentration of said *ketoprofen* is at least
16 approximately 5%;
17 said clinical concentration of said *ketoprofen* is at most
18 approximately 20%;
19 a clinical concentration of said *piroxicam* is at least
20 approximately 0.5%; and
21 said clinical concentration of said *piroxicam* is at most
22 approximately 4%.

1 61. (withdrawn, original) The preparation of claim 60,
2 wherein:

3 said clinical concentration of said *phenylephrine* is
4 approximately 0.5%;
5 said clinical concentration of said *bupivacaine* is
6 approximately 5%;

7 said clinical concentration of said *ketoprofen* is
8 approximately 10%; and

9 said clinical concentration of said *piroxicam* is
10 approximately 1.0%.

1 62. (withdrawn, original) The preparation of claim 45,
2 additionally for treating a viral disease, said therapeutic
3 agent further comprising:
4 an antiviral agent.

1 63. (withdrawn, original) The preparation of claim 62:
2 said vasoconstrictor comprising *phenylephrine*;
3 said penetration enhancer comprising a penetration
4 enhancing agent selected from the penetration-enhancing agent
5 group consisting of *dimethylsulfoxide* and *lecithin*;
6 said local anesthetic comprising *bupivacaine*;
7 said quick-onset, short-acting non-steroidal anti-
8 inflammatory agent comprising *ketoprofen*;
9 said long-acting non-steroidal anti-inflammatory agent
10 comprising *piroxicam*; and
11 said antiviral agent comprising *2-deoxy-d-glucose*.

1 64. (withdrawn, original) The preparation of claim 63,
2 wherein:

3 a clinical concentration of said *phenylephrine* is at least
4 approximately 0.125%;
5 said clinical concentration of said *phenylephrine* is at

6 most approximately 1.0%;
7 a clinical concentration of said *dimethylsulfoxide* is at
8 most approximately 10%;
9 a clinical concentration of said *lecithin* is at most
10 approximately 50%;
11 a clinical concentration of said *bupivacaine* is at least
12 approximately 2%;
13 said clinical concentration of said *bupivacaine* is at most
14 approximately 10%;
15 a clinical concentration of said *ketoprofen* is at least
16 approximately 5%;
17 said clinical concentration of said *ketoprofen* is at most
18 approximately 20%;
19 a clinical concentration of said *piroxicam* is at least
20 approximately 0.5%;
21 said clinical concentration of said *piroxicam* is at most
22 approximately 4%;
23 a clinical concentration of said *2-deoxy-d-glucose* is at
24 least approximately 0.1%; and
25 said clinical concentration of said *2-deoxy-d-glucose* is at
26 most approximately 0.4%.

1 65. (withdrawn, original) The preparation of claim 64,
2 wherein:
3 said clinical concentration of said *phenylephrine* is

4 approximately 0.5%;
5 said clinical concentration of said *bupivacaine* is
6 approximately 5%;
7 said clinical concentration of said *ketoprofen* is
8 approximately 10%;
9 said clinical concentration of said *piroxicam* is
10 approximately 1.0%; and
11 said clinical concentration of said *2-deoxy-d-glucose* is
12 approximately 0.2%.

1 66. (withdrawn, currently amended) A method of topically
2 | delivering and localizing at least one therapeutic agent, ,
3 comprising:

4 using a vasoconstrictor for retarding vascular dispersion
5 of a therapeutic agent, selected from the vasoconstrictor group
6 consisting of at least one of: *phenylephrine*, *ephedrine sulfate*,
7 *epinephrine*, *naphazoline*, and *oxymetazoline*; in combination with
8 using a penetration enhancer for facilitating penetration
9 of said vasoconstrictor and said therapeutic agent through a
10 patient's skin, selected from the penetration enhancer group
11 consisting of at least one of: *lecithin* and *dimethylsulfoxide*;
12 wherein:

13 | said therapeutic agent is selected from the therapeutic
14 agent group consisting of at least one ~~of~~therapeutic agent in at
15 least one of the following therapeutic agent groups:

16 (a) a local anesthetic selected from the group consisting
17 of: bupivacaine, mepivacaine, levobupivacaine, ropivacaine,
18 chloroprocaine, procaine, lidocaine, etidocaine, benzocaine,
19 tetracaine, and prilocaine;

20 (b) a quick-onset, short-acting non-steroidal anti-
21 inflammatory agent selected from the group consisting of:
22 ketoprofen, diclofenac, diflunisal, etodolac, fenoprofen,
23 flurbiprofen, ibuprofen, indomethacin, and tolmetin;

24 (c) a long-acting non-steroidal anti-inflammatory agent _
25 selected from the group consisting of: piroxicam, celecoxib,
26 meloxicam, nabumetone, naproxen, oxaprozin, rofecoxib, sulindac,
27 and valdecoxib; and

28 (d) an antiviral agent selected from the group consisting
29 of: 2-deoxy-d-glucose, podofilox, acyclovir, penciclovir, and
30 docosanol.

1 67. (withdrawn, currently amended) The method of claim 66 ,
2 said step of using said vasoconstrictor further comprising the
3 step of using phenylephrine.

1 68. (withdrawn, currently amended) The method of claim 67,
2 further comprising the steps of:

3 using a clinical concentration of said phenylephrine, of at
4 least approximately 0.125%; and
5 using said clinical concentration of said phenylephrine, of
6 at most approximately 1.0%.

1 69. (withdrawn, currently amended) The method of claim 68,
2 | further comprising ~~the step of~~ using said clinical concentration
3 | of said phenylephrine, of approximately 0.5%.

1 70. (withdrawn, currently amended) The method of claim 66 ,
2 | said ~~step of~~ using said vasoconstrictor further comprising ~~the~~-
3 | ~~step of~~ using a vasoconstrictor selected from the
4 | vasoconstrictor group consisting of: ephedrine sulfate,
5 | epinephrine, naphazoline, and oxymetazoline.

1 71. (withdrawn, currently amended) The method of claim 66,
2 | said ~~step of~~ using said penetration enhancer further comprising-
3 | ~~the step of~~ using dimethylsulfoxide.

1 72. (withdrawn, currently amended) The method of claim 71,
2 | further comprising ~~the step of~~ using a clinical concentration of
3 | said dimethylsulfoxide, of at most approximately 10%.

1 73. (withdrawn, currently amended) The method of claim 72,
2 | further comprising ~~the step of~~ using said clinical concentration
3 | of said dimethylsulfoxide, of approximately 10%.

1 74. (withdrawn, currently amended) The method of claim 66,
2 | said ~~step of~~ using said penetration enhancer further comprising-
3 | ~~the step of~~ using comprising lecithin.

1 75. (withdrawn, currently amended) The method of claim 74,
2 | said ~~step of~~ using said penetration enhancer further comprising-
3 | ~~the step of~~ using ethoxy diglycol.

1 76. (withdrawn, currently amended) The method of claim 74,

2 | further comprising the steps of:

3 | using a clinical concentration of said lecithin, of at
4 | least approximately 2%; and

5 | using said clinical concentration of said lecithin, of at
6 | most approximately 50%.

1 | 77. (withdrawn, currently amended) The method of claim 76,

2 | further comprising the step of:

3 | using said clinical concentration of said lecithin, of
4 | approximately 10% to 12%.

1 | 78. (withdrawn, currently amended) The method of claim 66:

2 | said step of using said vasoconstrictor further comprising-
3 | the step of using phenylephrine; and
4 | said step of using said penetration enhancer further
5 | comprising the step of using dimethylsulfoxide.

1 | 79. (withdrawn, currently amended) The method of claim 78,

2 | further comprising the steps of:

3 | using a clinical concentration of said phenylephrine, of at
4 | least approximately 0.125%;

5 | using said clinical concentration of said phenylephrine, of
6 | at most approximately 1.0%; and

7 | using a clinical concentration of said dimethylsulfoxide,
8 | of at most approximately 10%.

1 | 80. (withdrawn, currently amended) The method of claim 79,

2 | further comprising the steps of:

3 using said clinical concentration of said *phenylephrine*, of
4 approximately 0.5%; and

5 using said clinical concentration of said
6 *dimethylsulfoxide*, of approximately 10%.

1 81. (withdrawn, currently amended) The method of claim 78,
2 further comprising ~~the step of~~:

3 using a ratio of a clinical concentration of said
4 *dimethylsulfoxide* to a clinical concentration of said
5 *phenylephrine*, of at most approximately 40 to 1.

1 82. (withdrawn, currently amended) The method of claim 66:

2 said ~~step of~~ using said vasoconstrictor further comprising-
3 ~~the step of~~ using *phenylephrine*; and
4 said ~~step of~~ using said penetration enhancer further
5 comprising ~~the step of~~ using *lecithin*.

1 83. (withdrawn, currently amended) The method of claim 82,
2 said ~~step of~~ using said penetration enhancer further comprising-
3 ~~the step of~~ using *ethoxy diglycol*.

1 84. (withdrawn, currently amended) The method of claim 82,
2 further comprising ~~the steps of~~:

3 using a clinical concentration of said *phenylephrine*, of at
4 least approximately 0.125%;

5 using said clinical concentration of said *phenylephrine*, of
6 at most approximately 1.0%; and

7 using a clinical concentration of said *lecithin*, of at most

8 approximately 50%.

1 85. (withdrawn, currently amended) The method of claim 84,

2 | further comprising ~~the steps of~~:

3 using said clinical concentration of said *phenylephrine*, of
4 approximately 0.5%; and

5 using said clinical concentration of said *lecithin*, of
6 approximately 10% to 12%.

1 86. (withdrawn, currently amended) The method of claim 82,

2 | further comprising ~~the step of~~:

3 using a ratio of a clinical concentration of said *lecithin*
4 to a clinical concentration of said *phenylephrine*, of at most
5 approximately 200 to 1.

1 87. (withdrawn, currently amended) The method of claim 66,

2 | further comprising ~~the step of~~:

3 using said therapeutic agent in combination with using said
4 vasoconstrictor and using said penetration enhancer.

1 88. (withdrawn, currently amended) The method of claim 87,

2 particularly for relieving pain:

3 | said ~~step of~~ using said therapeutic agent further
4 comprising ~~the step of~~ using a therapeutic pain-relieving agent;
5 further comprising ~~the steps of~~:

6 using said penetration enhancer for facilitating
7 penetration of said therapeutic pain-relieving agent and said
8 vasoconstrictor through the patient's skin; and

9 using said vasoconstrictor for retarding vascular
10 dispersion of said therapeutic agent.

1 89. (withdrawn, currently amended) The method of claim 88,
2 | ~~said step of~~ using said therapeutic pain-relieving agent further
3 | ~~comprising the step of~~ using a local anesthetic.

1 90. (withdrawn, currently amended) The method of claim 89,
2 | ~~said step of~~ using said local anesthetic further comprising ~~the~~
3 | ~~step of~~ using bupivacaine.

1 91. (withdrawn, currently amended) The method of claim 90,
2 | further comprising ~~the steps of~~:

3 using a clinical concentration of said bupivacaine, of at
4 least approximately 2%; and
5 using said clinical concentration of said bupivacaine, of
6 at most approximately 10%.

1 92. (withdrawn, currently amended) The method of claim 91,
2 | further comprising ~~the step of~~ using said clinical concentration
3 | of said bupivacaine, of approximately 5%.

1 93. (withdrawn, currently amended) The method of claim 89,
2 | ~~said step of~~ using said local anesthetic further comprising ~~the~~
3 | ~~step of~~ using a local anesthetic selected from the local
4 | anesthetic group consisting of: *mepivacaine, levobupivacaine,*
5 | *ropivacaine, chloroprocaine, procaine, lidocaine, etidocaine,*
6 | *benzocaine, tetracaine, and prilocaine.*

1 94. (withdrawn, currently amended) The method of claim 88,

2 | said-step-of using said therapeutic pain-relieving agent
3 | further comprising-the-step-of using a quick-onset, short-acting
4 | non-steroidal anti-inflammatory agent.

1 | 95. (withdrawn, currently amended) The method of claim 94,
2 | said-step-of using said quick-onset, short-acting non-steroidal
3 | anti-inflammatory agent further comprising-the-step-of using
4 | *ketoprofen*.

1 | 96. (withdrawn, currently amended) The method of claim 95,
2 | further comprising-the-step-of:
3 | using a clinical concentration of said *ketoprofen*, of at
4 | least approximately 5%; and
5 | said clinical concentration of said *ketoprofen*, of at most
6 | approximately 20%.

1 | 97. (withdrawn, currently amended) The method of claim 96,
2 | further comprising-the-step-of using said clinical concentration
3 | of said *ketoprofen*, of approximately 10%.

1 | 98. (withdrawn, currently amended) The method of claim 94,
2 | said-step-of using said quick-onset, short-acting non-steroidal
3 | anti-inflammatory agent further comprising-the-step-of using a
4 | quick-onset, short-acting non-steroidal anti-inflammatory agent
5 | selected from the quick-onset, short-acting non-steroidal anti-
6 | inflammatory agent group consisting of: *diclofenac*, *diflunisal*,
7 | *etodolac*, *fenoprofen*, *flurbiprofen*, *ibuprofen*, *indomethacin*, and
8 | *tolmetin*.

1 99. (withdrawn, currently amended) The method of claim 88,
2 | ~~said step of~~ using said therapeutic pain-relieving agent further
3 | comprising ~~the step of~~ using a long-acting non-steroidal anti-
4 | inflammatory agent.

1 100. (withdrawn, currently amended) The method of claim 99,
2 | ~~said step of~~ using said long-acting non-steroidal anti-
3 | inflammatory agent further comprising ~~the step of~~ using
4 | piroxicam.

1 101. (withdrawn, currently amended) The method of claim 100,
2 | further comprising ~~the steps of~~:

3 | using a clinical concentration of said piroxicam, of at
4 | least approximately 0.5%; and
5 | using said clinical concentration of said piroxicam, of at
6 | most approximately 4%.

1 102. (withdrawn, currently amended) The method of claim 101,
2 | further comprising ~~the step of~~ using said clinical concentration
3 | of said piroxicam, of approximately 1.0%.

1 103. (withdrawn, currently amended) The method of claim 99,
2 | ~~said step of~~ using said long-acting non-steroidal anti-
3 | inflammatory agent further comprising ~~the step of~~ using a long-
4 | acting non-steroidal anti-inflammatory agent selected from the
5 | long-acting non-steroidal anti-inflammatory agent group
6 | consisting of: celecoxib, meloxicam, nabumetone, naproxen,
7 | oxaprozin, rofecoxib, sulindac, and valdecoxib.

1 104. (withdrawn, currently amended) The method of claim 88,
2 ~~said step of~~ using said therapeutic pain-relieving agent further
3 comprising the steps of:

4 using a local anesthetic; and

5 using a quick-onset, short-acting non-steroidal anti-
6 inflammatory agent.

1 105. (withdrawn, currently amended) The method of claim 104:

2 ~~said step of~~ using said local anesthetic further comprising-
3 ~~the step of~~ using bupivacaine; and

4 ~~said step of~~ using said quick-onset, short-acting non-
5 steroid anti-inflammatory agent further comprising ~~the step of~~
6 using ketoprofen.

1 106. (withdrawn, currently amended) The method of claim 88,
2 ~~said step of~~ using said therapeutic pain-relieving agent further
3 comprising ~~the steps of~~::

4 using a local anesthetic; and

5 using a long-acting non-steroidal anti-inflammatory agent.

1 107. (withdrawn, currently amended) The method of claim 106:

2 ~~said step of~~ using said local anesthetic further comprising-
3 ~~the step of~~ using bupivacaine; and

4 ~~said step of~~ using said long-acting non-steroidal anti-
5 inflammatory agent further comprising ~~the step of~~ using
6 piroxicam.

1 108. (withdrawn, currently amended) The method of claim 88,

2 | said-step-of using said therapeutic pain-relieving agent further
3 | comprising the steps of::

4 | using a quick-onset, short-acting non-steroidal anti-
5 | inflammatory agent; and

6 | using a long-acting non-steroidal anti-inflammatory agent.

1 | 109. (withdrawn, currently amended) The method of claim 108:

2 | said-step-of using said quick-onset, short-acting non-
3 | steroid anti-inflammatory agent further comprising the step of
4 | using ketoprofen; and

5 | said-step-of using said long-acting non-steroidal anti-
6 | inflammatory agent further comprising the step of using
7 | piroxicam.

1 | 110. (withdrawn, currently amended) The method of claim 88,
2 | said-step-of using said therapeutic pain-relieving agent further
3 | comprising the steps of:

4 | using a local anesthetic;

5 | using a quick-onset, short-acting non-steroidal anti-
6 | inflammatory agent; and

7 | using a long-acting non-steroidal anti-inflammatory agent.

1 | 111. (withdrawn, currently amended) The method of claim 110:

2 | said-step-of using said local anesthetic further comprising-
3 | the step of using bupivacaine;

4 | said-step-of using said quick-onset, short-acting non-
5 | steroid anti-inflammatory agent further comprising the step of

6 using *ketoprofen*; and

7 | ~~said step of~~ using said long-acting non-steroidal anti-
8 | inflammatory agent further comprising ~~the step of~~ using
9 | *piroxicam*.

1 112. (withdrawn, currently amended) The method of claim 111,
2 | further comprising ~~the steps of~~:

3 | using a clinical concentration of said *bupivacaine*, of at
4 | least approximately 2%;

5 | using said clinical concentration of said *bupivacaine*, of at
6 | at most approximately 10%;

7 | using a clinical concentration of said *ketoprofen*, of at
8 | least approximately 5%;

9 | using said clinical concentration of said *ketoprofen*, of at
10 | most approximately 20%;

11 | using a clinical concentration of said *piroxicam*, of at
12 | least approximately 0.5%; and

13 | using said clinical concentration of said *piroxicam*, of at
14 | most approximately 4%.

1 113. (withdrawn, currently amended) The method of claim 112,
2 | further comprising ~~the steps of~~:

3 | using said clinical concentration of said *bupivacaine*, of
4 | approximately 5%;

5 | using said clinical concentration of said *ketoprofen*, of
6 | approximately 10%; and

7 using said clinical concentration of said *piroxicam*, of
8 approximately 1.0%.

1 114. (withdrawn, currently amended) The method of claim 87,
2 particularly for treating a viral disease:

3 ~~said step of~~ using said therapeutic agent further
4 comprising ~~the step of~~ using an antiviral agent; further
5 comprising ~~the steps of~~:

6 using said penetration enhancer for facilitating
7 penetration of said antiviral agent and said vasoconstrictor
8 through the patient's skin; and

9 using said vasoconstrictor for retarding vascular
10 dispersion of said antiviral agent.

1 115. (withdrawn, currently amended) The method of claim 114,
2 ~~said step of~~ using said antiviral agent further comprising ~~the~~
3 ~~step of~~ using 2-deoxy-d-glucose.

1 116. (withdrawn, currently amended) The method of claim 115,
2 further comprising ~~the steps of~~:

3 using a clinical concentration of said 2-deoxy-d-glucose,
4 of at least approximately 0.1%; and
5 using said clinical concentration of said 2-deoxy-d-
6 glucose, of at most approximately 0.4%.

1 117. (withdrawn, currently amended) The method of claim 116,
2 further comprising ~~the step of~~:

3 using said clinical concentration of said 2-deoxy-d-

4 glucose, of approximately 0.2%.

1 118. (withdrawn, currently amended) The method of claim 114,
2 ~~said step of~~ using said antiviral agent further comprising ~~the~~
3 ~~step of~~ using an antiviral agent selected from the antiviral
4 agent group consisting of: *podofilox, acyclovir, penciclovir,*
5 and *docosanol.*

1 119. (withdrawn, currently amended) The method of claim 88,
2 particularly for relieving pain from a viral disease and
3 treating the viral disease:

4 ~~said step of~~ using said therapeutic agent further
5 comprising ~~the step of~~ using an antiviral agent; further
6 comprising ~~the steps of~~:

7 using said penetration enhancer for further facilitating
8 penetration of said antiviral agent through the patient's skin;
9 and

10 using said vasoconstrictor for further retarding vascular
11 dispersion of said antiviral agent.

1 120. (withdrawn, currently amended) The method of claim 119,
2 ~~said step of~~ using said antiviral agent further comprising ~~the~~
3 ~~step of~~ using *2-deoxy-d-glucose.*

1 121. (withdrawn, currently amended) The method of claim 120,
2 further comprising ~~the steps of~~:
3 using a clinical concentration of said *2-deoxy-d-glucose,*
4 of at least approximately 0.1%; and

5 using said clinical concentration of said 2-deoxy-d-
6 glucose, of at most approximately 0.4%.

1 122. (withdrawn, currently amended) The method of claim 121,

2 | further comprising ~~the step of~~:

3 using said clinical concentration of said 2-deoxy-d-
4 glucose, of approximately 0.2%.

1 123. (withdrawn, currently amended) The method of claim 119,

2 | ~~said step of~~ using said antiviral agent further comprising ~~the~~
3 ~~step of~~ using an antiviral agent selected from the antiviral
4 agent group consisting of: *podofilox, acyclovir, penciclovir,*
5 and *docosanol*.

1 124. (withdrawn, currently amended) The method of claim 110:

2 ~~said step of~~ using said vasoconstrictor further comprising-
3 ~~the step of~~ using *phenylephrine*;

4 ~~said step of~~ using said penetration enhancer further
5 comprising ~~the step of~~ using a penetration enhancing agent
6 selected from the penetration-enhancing agent group consisting
7 of *dimethylsulfoxide* and *lecithin*;

8 ~~said step of~~ using said local anesthetic further comprising-
9 ~~the step of~~ using *bupivacaine*;

10 ~~said step of~~ using said quick-onset, short-acting non-
11 steroidal anti-inflammatory agent further comprising ~~the step of~~
12 using *ketoprofen*; and

13 ~~said step of~~ using said long-acting non-steroidal anti-

14 | inflammatory agent further comprising ~~the step of~~ using
15 | *piroxicam*.

1 | 125. (withdrawn, currently amended) The method of claim 124,
2 | further comprising ~~the steps of~~:

3 | using a clinical concentration of said *phenylephrine*, of at
4 | least approximately 0.125%;

5 | using said clinical concentration of said *phenylephrine*, of
6 | at most approximately 1.0%;

7 | using a clinical concentration of said *dimethylsulfoxide*,
8 | of at most approximately 10%;

9 | using a clinical concentration of said *lecithin*, of at most
10 | approximately 50%;

11 | using a clinical concentration of said *bupivacaine*, of at
12 | least approximately 2%;

13 | using said clinical concentration of said *bupivacaine*, of
14 | at most approximately 10%;

15 | using a clinical concentration of said *ketoprofen*, of at
16 | least approximately 5%;

17 | using said clinical concentration of said *ketoprofen*, of at
18 | most approximately 20%;

19 | using a clinical concentration of said *piroxicam*, of at
20 | least approximately 0.5%; and

21 | using said clinical concentration of said *piroxicam*, of at
22 | most approximately 4%.

1 126. (withdrawn, currently amended) The method of claim 125,
2 further comprising ~~the steps of:~~
3 using said clinical concentration of said *phenylephrine*, of
4 approximately 0.5%;
5 using said clinical concentration of said *bupivacaine*, of
6 approximately 5%;
7 using said clinical concentration of said *ketoprofen*, of
8 approximately 10%; and
9 using said clinical concentration of said *piroxicam*, of
10 approximately 1.0%.

1 127. (withdrawn, currently amended) The method of claim 110,
2 additionally for treating a viral disease, ~~said step of~~ using
3 said therapeutic agent further comprising ~~the step of~~ using an
4 antiviral agent.

1 128. (withdrawn, currently amended) The method of claim 127:
2 ~~said step of~~ using said vasoconstrictor further comprising-
3 ~~the step of~~ using *phenylephrine*;
4 ~~said step of~~ using said penetration enhancer further
5 comprising ~~the step of~~ using a penetration enhancing agent
6 selected from the penetration-enhancing agent group consisting
7 of *dimethylsulfoxide* and *lecithin*;
8 ~~said step of~~ using said local anesthetic further comprising-
9 ~~the step of~~ using *bupivacaine*;
10 ~~said step of~~ using said quick-onset, short-acting non-

11 | steroid anti-inflammatory agent further comprising ~~the step of~~
12 | using *ketoprofen*;

13 | ~~said step of~~ using said long-acting non-steroidal anti-
14 | inflammatory agent further comprising ~~the step of~~ using
15 | *piroxicam*; and

16 | ~~said step of~~ using said antiviral agent further comprising-
17 | ~~the step of~~ using *2-deoxy-d-glucose*.

1 | 129. (withdrawn, currently amended) The method of claim 128,
2 | further comprising ~~the steps of~~:

3 | using a clinical concentration of said *phenylephrine*, of at
4 | least approximately 0.125%;

5 | using said clinical concentration of said *phenylephrine*, of
6 | at most approximately 1.0%;

7 | using a clinical concentration of said *dimethylsulfoxide*,
8 | of at most approximately 10%;

9 | using a clinical concentration of said *lecithin*, of at most
10 | approximately 50%;

11 | using a clinical concentration of said *bupivacaine*, of at
12 | least approximately 2%;

13 | using said clinical concentration of said *bupivacaine*, of
14 | at most approximately 10%;

15 | using a clinical concentration of said *ketoprofen*, of at
16 | least approximately 5%;

17 | using said clinical concentration of said *ketoprofen*, of at

18 most approximately 20%;
19 using a clinical concentration of said *piroxicam*, of at
20 least approximately 0.5%;
21 using said clinical concentration of said *piroxicam*, of at
22 most approximately 4%;
23 using a clinical concentration of said *2-deoxy-d-glucose*,
24 of at least approximately 0.1%; and
25 using said clinical concentration of said *2-deoxy-d-*
26 *glucose*, of at most approximately 0.4%.

1 130. (withdrawn, currently amended) The method of claim 129,

2 | further comprising ~~the steps of~~:

3 using said clinical concentration of said *phenylephrine*, of
4 approximately 0.5%;
5 using said clinical concentration of said *bupivacaine*, of
6 approximately 5%;

7 using said clinical concentration of said *ketoprofen*, of
8 approximately 10%;

9 using said clinical concentration of said *piroxicam*, of
10 approximately 1.0%; and

11 using said clinical concentration of said *2-deoxy-d-*
12 *glucose*, of approximately 0.2%.

1 131. (withdrawn, currently amended) The method of claim 66,

2 | further comprising ~~the step of~~:

3 applying said vasoconstrictor and said penetration enhancer

4 to the patient's skin.

1 132. (withdrawn, currently amended) The method of claim 78,

2 | further comprising the step of:

3 applying said *phenylephrine* and said *dimethylsulfoxide* to
4 the patient's skin.

1 133. (withdrawn, currently amended) The method of claim 82,

2 | further comprising the step of:

3 applying said *phenylephrine* and said *lecithin* to the
4 patient's skin.

1 134. (withdrawn, currently amended) The method of claim 87,

2 | further comprising the step of:

3 applying said vasoconstrictor, said penetration enhancer,
4 and said therapeutic agent to the patient's skin.

1 135. (withdrawn, currently amended) The method of claim 88,

2 | further comprising the step of:

3 applying said vasoconstrictor, said penetration enhancer,
4 and said therapeutic pain-relieving agent to the patient's skin.

1 136. (withdrawn, currently amended) The method of claim 89,

2 | further comprising the step of:

3 applying said vasoconstrictor, said penetration enhancer,
4 and said local anesthetic to the patient's skin.

1 137. (withdrawn, currently amended) The method of claim 90,

2 | further comprising the step of:

3 applying said vasoconstrictor, said penetration enhancer,

4 and said bupivacaine to the patient's skin.

1 138. (withdrawn, currently amended) The method of claim 94,

2 | further comprising the step of:

3 applying said vasoconstrictor, said penetration enhancer,

4 and said quick-onset, short-acting non-steroidal anti-

5 inflammatory agent to the patient's skin.

1 139. (withdrawn, currently amended) The method of claim 95,

2 | further comprising the step of:

3 applying said vasoconstrictor, said penetration enhancer,

4 and said ketoprofen to the patient's skin.

1 140. (withdrawn, currently amended) The method of claim 99,

2 | further comprising the step of:

3 applying said vasoconstrictor, said penetration enhancer,

4 and said long-acting non-steroidal anti-inflammatory agent to

5 the patient's skin.

1 141. (withdrawn, currently amended) The method of claim 100,

2 | further comprising the step of:

3 applying said vasoconstrictor, said penetration enhancer,

4 and said piroxicam to the patient's skin.

1 142. (withdrawn, currently amended) The method of claim 110,

2 | further comprising the step of:

3 applying said vasoconstrictor, said penetration enhancer,

4 said local anesthetic, said quick-onset, short-acting non-

5 steroidal anti-inflammatory agent, and said long-acting non-

6 steroidal anti-inflammatory agent to the patient's skin.

1 143. (withdrawn, currently amended) The method of claim 111,
2 | further comprising the step of:

3 applying said vasoconstrictor, said penetration enhancer,
4 said *bupivacaine*, said *ketoprofen*, and said *piroxicam* to the
5 patient's skin.

1 144. (withdrawn, currently amended) The method of claim 114,
2 | further comprising the step of:

3 applying said vasoconstrictor, said penetration enhancer,
4 and said antiviral agent to the patient's skin.

1 145. (withdrawn, currently amended) The method of claim 115,
2 | further comprising the step of:

3 applying said vasoconstrictor, said penetration enhancer,
4 and said *2-deoxy-d-glucose* to the patient's skin.

1 146. (withdrawn, currently amended) The method of claim 119,
2 | further comprising the step of:

3 applying said vasoconstrictor, said penetration enhancer,
4 therapeutic pain-relieving agent, and said antiviral agent to
5 the patient's skin.

1 147. (withdrawn, currently amended) The method of claim 120,
2 | further comprising the step of:

3 applying said vasoconstrictor, said penetration enhancer,
4 therapeutic pain-relieving agent, and said *2-deoxy-d-glucose* to
5 the patient's skin.

1 148. (withdrawn, currently amended) The method of claim 124,
2 | further comprising ~~the step of:~~:
3 | applying said *phenylephrine*, said penetration enhancing
4 | agent selected from the penetration-enhancing agent group
5 | consisting of *dimethylsulfoxide* and *lecithin*, said *bupivacaine*,
6 | said *ketoprofen*, and said *piroxicam* to the patient's skin.

1 149. (withdrawn, currently amended) The method of claim 127,
2 | further comprising ~~the step of:~~:
3 | applying said *vasoconstrictor*, said penetration enhancer,
4 | said local anesthetic, said quick-onset, short-acting non-
5 | steroid anti-inflammatory agent, said long-acting non-
6 | steroid anti-inflammatory agent, and said antiviral agent to
7 | the patient's skin.

1 150. (withdrawn, currently amended) The method of claim 128,
2 | further comprising ~~the step of:~~:
3 | applying said *phenylephrine*, said penetration enhancing
4 | agent selected from the penetration-enhancing agent group
5 | consisting of *dimethylsulfoxide* and *lecithin*, said *bupivacaine*,
6 | said *ketoprofen*, said *piroxicam*; and said *2-deoxy-d-glucose* to
7 | the patient's skin.